<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472521</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-43964</org_study_id>
    <nct_id>NCT03472521</nct_id>
  </id_info>
  <brief_title>Prevention of Persistent Opioid Use in Mothers</brief_title>
  <official_title>Prevention of Persistent Pain and Opioid Use in Mothers - POMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our previous work has identified the group of women at risk for prolonged pain, opioid use
      and poor functional recovery after childbirth. The optimal intervention to mitigate this risk
      is unknown. We propose to test an analgesic adjutant that is commonly used for post-operative
      pain compared to placebo to improve post-partum recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A small percent of the large population of women who give birth have difficulty with
      prolonged pain, opioid use and poor functional recovery. This may be the first opiate
      exposure and significant health challenge in a young woman's life.

      In our previous work, we have identified 20% who are at highest risk for prolonged pain and
      delayed opioid cessation and functional recovery with usual care. Moderate to severe pain on
      postpartum day 1 is a significant predictor of being in the risk group.The optimal
      intervention to mitigate this risk is unknown.

      We plan to test an intervention of low dose gabapentin or placebo to be escalated by a pain
      medicine doctor as needed. We hypothesize that additional care of women predicted to be
      higher need by virtue of their postoperative day one pain score (&gt;6 x2) despite usual
      multimodal analgesic care will lead to reduced need for opioid, less pain and more rapid
      functional recovery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A randomization table will be used by the research pharmacy and study drug will be prepared in numbered bottles.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Utilization</measure>
    <time_frame>12 weeks</time_frame>
    <description>Opioid utilization will be primarily in days and secondarily in mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Report</measure>
    <time_frame>12 weeks</time_frame>
    <description>Average pain will be reported on a numerical rating scale daily and compared as area under the curve of pain/days or time to cessation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional recovery</measure>
    <time_frame>12 weeks</time_frame>
    <description>Functional will be assessed with the PROMIS Physical Function questionaire. Functional recovery will be assessed as the number of days to return to pre-delivery function.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fatigue</measure>
    <time_frame>12 weeks</time_frame>
    <description>PROMIS Fatigue 4 questionaire will be used to assess fatigue as a modifier of the above outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Depression</measure>
    <time_frame>12 weeks</time_frame>
    <description>PROMIS Depression 4 questionnaire will be used to assess fatigue as a modifier of the above outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Anxiety</measure>
    <time_frame>12 weeks</time_frame>
    <description>PROMIS Anxiety 4 questionaire will be used to assess fatigue as a modifier of the above outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Steps</measure>
    <time_frame>12 weeks after delivery</time_frame>
    <description>Fitness tracker measured steps</description>
  </other_outcome>
  <other_outcome>
    <measure>sleep</measure>
    <time_frame>12 weeks after delivery</time_frame>
    <description>Fitness tracker measured sleep</description>
  </other_outcome>
  <other_outcome>
    <measure>heart rate</measure>
    <time_frame>12 weeks after delivery</time_frame>
    <description>Fitness tracker measured heart rate</description>
  </other_outcome>
  <other_outcome>
    <measure>PROMIS physical function</measure>
    <time_frame>12 weeks after delivery</time_frame>
    <description>PROMIS Physical Function questionaire will be used to assess fatigue as a modifier of the above outcomes.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Opioid Use</condition>
  <condition>Postpartum Disorder</condition>
  <condition>Chronic Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Treatment with analgesic adjutant commonly used for post-operative pain, titrated to effect by chronic pain specialist compared to placebo titration.</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match gabapentin</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Delivery within 5 days, able to provide informed consent, English speaker

        Exclusion Criteria:

          -  Opiate use disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Flood, MD, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela Flood, MD, MA</last_name>
    <phone>201-370-3933</phone>
    <email>pflood@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brendan Carvalho, MBBCh, MDCH</last_name>
    <phone>650-861-8607</phone>
    <email>carvalb@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lucille Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Araseli Hernandez</last_name>
      <phone>650-723-5439</phone>
      <email>araselih@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Flood, MD,MA</last_name>
      <phone>201-370-3933</phone>
      <email>pflood@stanford.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Komatsu R, Carvalho B, Flood PD. Recovery after Nulliparous Birth: A Detailed Analysis of Pain Analgesia and Recovery of Function. Anesthesiology. 2017 Oct;127(4):684-694. doi: 10.1097/ALN.0000000000001789.</citation>
    <PMID>28926443</PMID>
  </reference>
  <reference>
    <citation>Komatsu R, Carvalho B, Flood P. Prediction of outliers in pain, analgesia requirement, and recovery of function after childbirth: a prospective observational cohort study. Br J Anaesth. 2018 Aug;121(2):417-426. doi: 10.1016/j.bja.2018.04.033.</citation>
    <PMID>30032880</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Pamela Flood</investigator_full_name>
    <investigator_title>Professor, Anesthesiology, Perioperative and Pain Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puerperal Disorders</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

